Centaurus Financial’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,440
Closed -$137K 918
2024
Q3
$137K Sell
1,440
-20
-1% -$1.9K 0.01% 751
2024
Q2
$134K Buy
1,460
+70
+5% +$6.25K 0.01% 710
2024
Q1
$126K Buy
+1,390
New +$122K 0.01% 714
2018
Q3
Sell
-16
Closed -$1K 1646
2018
Q2
$1K Buy
+16
New +$927 ﹤0.01% 2132

Other funds holding PPH

Centaurus Financial's PPH Position: Q4 2024 in Review

Centaurus Financial sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2024, closing a stake of 1,440 shares — an estimated $137K sold.

Centaurus Financial first reported a position in PPH in Q2 2018 and held it in 4 quarters. The position peaked at $137K in Q3 2024. 142 funds tracked by Wall St. Rank hold PPH as of Q4 2024.

  • Centaurus Financial reported no remaining VanEck Pharmaceutical ETF position as of Q4 2024 after selling out during the quarter.
  • Centaurus Financial sold 1,440 VanEck Pharmaceutical ETF shares in Q4 2024, an estimated $137K.
  • Centaurus Financial first reported a position in VanEck Pharmaceutical ETF in Q2 2018 and held it in 4 quarters.
  • Centaurus Financial's VanEck Pharmaceutical ETF position peaked at $137K in Q3 2024.
  • 142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2024.

Based on Centaurus Financial's 13F filing for Q4 2024, filed 12 Mar 2025.